Anaptys (ANAB) Reports Third Quarter 2025 Financial Earnings Results And Provides Business Update

AnaptysBio, Inc. (ANAB) today announced its financial results for the most recent quarter, revealing an earnings per share (EPS) of $0.52, significantly surpassing analysts’ expectations by $1.73. However, the company reported revenue of $2.92 million, falling short of the estimated $21.92 million. Despite the revenue miss, AnaptysBio’s strong EPS performance highlights its ability to exceed profitability forecasts in a challenging market environment.

Key Highlights:

• AnaptysBio intends to separate its biopharma operations from its royalty assets by the end of 2026.
• Phase 2 top-line data for rosnilimab in ulcerative colitis is expected in November/December 2025.
• Rosnilimab’s Phase 2b data in rheumatoid arthritis was presented at ACR Convergence 2025.
• GSK reported strong sales for Jemperli, with $303 million in Q3 2025 and $785 million year-to-date.
• Anaptys anticipates a one-time $75 million milestone from GSK when Jemperli achieves $1 billion in sales.
• The company expects over $390 million in annualized royalties from Jemperli at peak sales guidance.

AnaptysBio, Inc. has announced its intent to separate its biopharma operations from its substantial royalty assets by the end of 2026. This strategic move aims to unlock potential value by creating two independent, publicly traded companies, allowing investors to align their investment strategies with the distinct objectives of each entity. Daniel Faga, the CEO, emphasized that this separation will enhance the potential value of both sets of assets, particularly highlighting the strong performance of Jemperli, which has seen significant sales growth.

In terms of product development, AnaptysBio is making progress with its lead program, rosnilimab, which is currently in Phase 2 trials for ulcerative colitis and has shown promising results in rheumatoid arthritis. The company is also advancing its pipeline with ANB033, a CD122 antagonist, and ANB101, a BDCA2 modulator. Financially, Anaptys reported collaboration revenue of $76.3 million for Q3 2025, driven by Jemperli’s sales, and anticipates a cash runway of approximately $300 million by the end of 2025, bolstered by expected milestone payments.

AnaptysBio, Inc. (ANAB) has experienced a rollercoaster ride in its stock price, showcasing a remarkable one-year increase of 74.22%, despite a recent dip of 3.93% over the past week. This volatility can be attributed to the company’s impressive revenue growth, with a two-year compound annual growth rate (CAGR) of 208.57%, indicating strong operational momentum. However, the negative price-to-earnings ratio of -7.87 and a troubling return on invested capital of -25.69% raise concerns about profitability and capital efficiency. The net profit margin of -1.19% further underscores the challenges AnaptysBio faces in converting revenue into profit. While the stock has shown resilience with a 63.95% increase over the past six months, investors should remain cautious, as the fundamentals suggest that the company still has significant hurdles to overcome. Overall, while the upward price trajectory is encouraging, the underlying financial metrics highlight a need for improvement in profitability and operational efficiency.

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.